Compare Stocks → Write this ticker symbol down… (From StocksToTrade) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATHENASDAQ:ELABNASDAQ:GHSINASDAQ:GRTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$1.95-2.5%$2.06$1.55▼$5.41$9.11M0.9368,315 shs9,734 shsELABElevai Labs$0.64-4.5%$0.66$0.57▼$4.24$12.09MN/A1.01 million shs249,925 shsGHSIGuardion Health Sciences$9.29+0.4%$8.47$5.01▼$10.75$11.89M0.9137,085 shs4,638 shsGRTXGalera Therapeutics$0.20+5.2%$0.18$0.09▼$3.59$11.10M2.022.00 million shs966,879 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-2.50%-0.57%-22.31%+2.36%-25.29%ELABElevai Labs-4.21%-5.19%-2.91%-8.56%+63,999,900.00%GHSIGuardion Health Sciences+0.43%+0.27%+17.59%+15.26%+44.25%GRTXGalera Therapeutics+4.08%+7.37%+9.62%-23.19%-93.29%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics3.4524 of 5 stars3.55.00.00.03.11.71.3ELABElevai LabsN/AN/AN/AN/AN/AN/AN/AN/AGHSIGuardion Health SciencesN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics3.00Buy$7.00258.97% UpsideELABElevai LabsN/AN/AN/AN/AGHSIGuardion Health Sciences2.00HoldN/AN/AGRTXGalera Therapeutics1.75ReduceN/AN/ACurrent Analyst RatingsLatest ELAB, ATHE, GHSI, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2024ATHEAlterity TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$4.00(Data available from 5/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity Therapeutics$3.37M2.70N/AN/A$3.78 per share0.52ELABElevai Labs$1.71M7.07N/AN/A$0.22 per share2.91GHSIGuardion Health Sciences$12.25M0.97$0.14 per share66.49$6.39 per share1.45GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$9.30MN/A0.00N/AN/AN/AN/AN/AN/AELABElevai Labs-$4.30M-$0.37N/A∞N/A-211.25%-225.32%-125.94%9/26/2024 (Estimated)GHSIGuardion Health Sciences$160K-$4.02N/A∞N/A-16.69%-77.29%-42.08%8/12/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.99N/A∞N/AN/AN/A-138.81%8/12/2024 (Estimated)Latest ELAB, ATHE, GHSI, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q1 2024ELABElevai LabsN/A-$0.08-$0.08-$0.08N/A$0.62 million3/29/2024Q4 2023ELABElevai LabsN/A-$0.08-$0.08-$0.08N/A$0.70 million3/28/2024Q4 2023GHSIGuardion Health SciencesN/A$0.33+$0.33$0.33N/A$21.56 million3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AELABElevai LabsN/AN/AN/AN/AN/AGHSIGuardion Health SciencesN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A4.89N/AELABElevai Labs0.202.571.80GHSIGuardion Health SciencesN/A8.176.49GRTXGalera TherapeuticsN/A7.547.54OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%ELABElevai Labs22.22%GHSIGuardion Health Sciences20.21%GRTXGalera Therapeutics50.77%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%ELABElevai LabsN/AGHSIGuardion Health Sciences1.32%GRTXGalera Therapeutics6.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics114.67 million2.86 millionNot OptionableELABElevai Labs1818.89 millionN/AN/AGHSIGuardion Health Sciences91.28 million1.27 millionNot OptionableGRTXGalera Therapeutics754.39 million50.64 millionOptionableELAB, ATHE, GHSI, and GRTX HeadlinesRecent News About These CompaniesMay 24, 2024 | americanbankingnews.comGalera Therapeutics (NASDAQ:GRTX) Shares Down 4.1% May 13, 2024 | globenewswire.comGalera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 11, 2024 | bovnews.comIs Galera Therapeutics Inc (GRTX) Stock A Better Investment Than Its Rivals?May 3, 2024 | finanznachrichten.deGalera Therapeutics: Galera Adopts Limited Duration Stockholder Rights AgreementMay 3, 2024 | globenewswire.comGalera Adopts Limited Duration Stockholder Rights AgreementApril 1, 2024 | msn.comGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory ChallengesMarch 28, 2024 | finanznachrichten.deGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | globenewswire.comGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 16, 2024 | finance.yahoo.comGRTX Apr 2024 0.500 callMarch 12, 2024 | nz.finance.yahoo.comGalera Therapeutics, Inc. (GRTX)February 27, 2024 | edition.cnn.comGalera Therapeutics, Inc.February 4, 2024 | investing.comGalera Therapeutics Inc (GRTX)February 4, 2024 | benzinga.comGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and DatesJanuary 21, 2024 | finance.yahoo.comGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17January 16, 2024 | bizjournals.comLocal publicly traded stocks lag far behind national indices in 2023January 9, 2024 | msn.comDow Tumbles Over 200 Points; US Trade Gap Narrows In NovemberNovember 28, 2023 | msn.comGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38November 14, 2023 | finanznachrichten.deGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 14, 2023 | benzinga.comGalera Therapeutics: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comGalera Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up Boston Scientific Bucks the Medtech Slow Down and Raises OutlookApril 30, 2024 10:34 AMView Boston Scientific Bucks the Medtech Slow Down and Raises OutlookNXP Semiconductors Will Set a New High Soon: $300 in SightApril 30, 2024 11:26 AMView NXP Semiconductors Will Set a New High Soon: $300 in SightMarketBeat Week in Review – 5/13 - 5/17May 18, 2024 7:00 AMView MarketBeat Week in Review – 5/13 - 5/17Shopify Stock Took a Breather, Markets Stay Bullish On its FutureMay 9, 2024 8:49 AMView Shopify Stock Took a Breather, Markets Stay Bullish On its FutureAll HeadlinesCompany DescriptionsAlterity TherapeuticsNASDAQ:ATHEAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Elevai LabsNASDAQ:ELABElevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Guardion Health SciencesNASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.